基于UPLC-MS/MS方法分析哈萨克族食管鳞癌患者的血清脂质组学特征

doi:10.3969/j.issn.1004-616x.2024.01.004

Abstract

Abstract: OBJECTIVE: To explore characteristics of lipid metabolism in Xinjiang Kazakh patients with esophageal squamous cell carcinoma(ESCC) based on serum lipidomics. METHODS: From January 2018 to December 2020, 30 Kazakh ESCC patients in the thoracic surgery department of the First Affiliated Hospital of Xinjiang Medical University(ESCC group) and 30 Kazakh healthy people who underwent physical examination in the Health Management Center of Xinjiang Medical University(control group) were selected.Ultra-high performance liquid chromatography-mass spectrometry(UPLC-MS/MS) was used to analyze the targeted quantitative lipidomics of serum in the two groups. Absolute lipid quantification was performed according to relationships between the peak areas and the actual concentrations of internal standard(IS) of similar lipids. Multivariate statistical analyses were performed using the lipid data. RESULTS: A total of 13lipids were screened out in 60 serum samples, among which triacylglycerol(TAG), phosphatidyl choline(PC)and phosphatidyl ethanolamine(PE) were the most abundant. Lysophosphatidylcholine(LPC) was the most different lipid in serum between the two groups. Compared with the control group, the levels of TAG and LPC in the serum of Kazakh ESCC patients were up-regulated, while PE was down-regulated. According to the orthogonal partial least squares-discriminant analysis(OPLS-DA), the threshold(P<0.05 and fold change>2 or <0.5), a total of 77 differential lipid metabolites were screened, among which 34 were up-regulated and 43 were down-regulated in ESCC group compared with control group. Including triglycerides, diglycerides, lysophosphatidyl choline, phosphatidyl ethanolamine and free fatty acids. CONCLUSION: The contents and trends of different lipids in the patients were different. The contents of triglyceride, phosphatidyl choline and ceramide in serum of patients were up-regulated, while the contents of lysatidyl choline and diglyceride were overall down-regulated. The contents of triglyceride and lysophosphatidyl choline in the serum of the Kazakh patients were up-regulated, while phosphatidyl ethanolamine was down-regulated, and the chain length and unsaturation of lysophosphatidyl choline, phosphatidyl ethanolamine and phosphatidyl choline were down-regulated in the serum of patients. Therefore, the analysis of changes in the distribution of these lipids and the screening of new targets are helpful to clarify mecahnisms for occurrence and development of ESCC patients of Xinjiang Kazak nationality.

Key words: esophageal squamous cell carcinoma, Kazakhs, lipidomics, lipid metabolites, differential expression

CLC Number:

R730.2

LIU Ruixue, LI Desheng, ZHANG Liwei. Characteristics of serum lipidomics among Kazakhs with esophageal squamous cell carcinomas based on the UPLC-MS/MS method[J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2024, 36(1): 21-28,34.

References

[1] SUNG H, FERLAY J, SIEGEL R L, et al. Global cancer statistics 2020:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3):209-249.
[2] 刘宗超,李哲轩,张阳,等. 2020全球癌症统计报告解读[J].肿瘤综合治疗电子杂志, 2021, 7(2):1-14.
[3] YANG S, LIN S, LI N, et al. Burden, trends, and risk factors of esophageal cancer in China from 1990 to 2017:an up-to-date overview and comparison with those in Japan and South Korea[J]. J Hematol Oncol, 2020, 13(1):146.
[4] NAPIER K J, SCHEERER M, MISRA S. Esophageal cancer:a Review of epidemiology, pathogenesis, staging workup and treatment modalities[J]. World J Gastrointest Oncol, 2014, 6(5):112-120.
[5] FATEHI HASSANABAD A, CHEHADE R, BREADNER D, et al. Esophageal carcinoma:towards targeted therapies[J]. Cell Oncol, 2020, 43(2):195-209.
[6] CHENG C M, GENG F, CHENG X, et al. Lipid metabolism reprogramming and its potential targets in cancer[J]. Cancer Commun, 2018, 38(1):27.
[7] LI W, WANG X B, ZHANG X B, et al. Revealing potential lipid biomarkers in clear cell renal cell carcinoma using targeted quantitative lipidomics[J]. Lipids Health Dis, 2021, 20(1):160.
[8] ZHANG Q, XU H R, LIU R, et al. A novel strategy for targeted lipidomics based on LC-tandem-MS parameters prediction,quantification, and multiple statistical data mining:evaluation of lysophosphatidylcholines as potential cancer biomarkers[J].Anal Chem, 2019, 91(5):3389-3396.
[9] SNAEBJORNSSON M T, JANAKI-RAMAN S, SCHULZE A.Greasing the wheels of the cancer machine:the role of lipid metabolism in cancer[J]. Cell Metab, 2020, 31(1):62-76.
[10] PERROTTI F, ROSA C, CICALINI I, et al. Advances in lipidomics for cancer biomarkers discovery[J]. Int J Mol Sci,2016, 17(12):1992.
[11] ZHANG H P, WANG L, HOU Z C, et al. Metabolomic profiling reveals potential biomarkers in esophageal cancer progression using liquid chromatography-mass spectrometry platform[J].Biochem Biophys Res Commun, 2017, 491(1):119-125.
[12] PARK J, CHOI J, KIM D D, et al. Bioactive lipids and their derivatives in biomedical applications[J]. Biomol Ther, 2021, 29(5):465-482.
[13] MANZO T, PRENTICE B M, ANDERSON K G, et al.Accumulation of long-chain fatty acids in the tumor microenvironment drives dysfunction in intrapancreatic CD8+T cells[J]. J Exp Med, 2020, 217(8):e20191920.
[14] WANG C C, TONG Y, WEN Y K, et al. Hepatocellular carcinoma-associated protein TD26 interacts and enhances sterol regulatory element-binding protein 1 activity to promote tumor cell proliferation and growth[J]. Hepatology, 2018, 68(5):1833-1850.
[15] LI J J, CONDELLO S, THOMES-PEPIN J, et al. Lipid desaturation is a metabolic marker and therapeutic target of ovarian cancer stem cells[J]. Cell Stem Cell, 2017, 20(3):303-314.e5.
[16] SZLASA W, ZENDRAN I, ZALESIŃSKA A, et al. Lipid composition of the cancer cell membrane[J]. J Bioenerg Biomembr, 2020, 52(5):321-342.
[17] XU J, CHEN Y H, ZHANG R P, et al. Global and targeted metabolomics of esophageal squamous cell carcinoma discovers potential diagnostic and therapeutic biomarkers[J]. Mol Cell Proteomics, 2013, 12(5):1306-1318.
[18] KÜHN T, FLOEGEL A, SOOKTHAI D, et al. Higher plasma levels of lysophosphatidylcholine 18:0 are related to a lower risk of common cancers in a prospective metabolomics study[J].BMC Med, 2016, 14:13.
[19] XIONG J H. Fatty acid oxidation in cell fate determination[J].Trends Biochem Sci, 2018, 43(11):854-857.
[20] YANG T, HUI R T, NOUWS J, et al. Untargeted metabolomics analysis of esophageal squamous cell cancer progression[J]. J Transl Med, 2022, 20(1):127.
[21] HOEJHOLT K L, MUŽIĆT, JENSEN S D, et al. Calcium electroporation and electrochemotherapy for cancer treatment:importance of cell membrane composition investigated by lipidomics, calorimetry and in vitro efficacy[J]. Sci Rep, 2019, 9(1):4758.
[22] HONSHO M, ABE Y, FUJIKI Y. Plasmalogen biosynthesis is spatiotemporally regulated by sensing plasmalogens in the inner leaflet of plasma membranes[J]. Sci Rep, 2017, 7:43936.
[23] ZHENG K H, CHEN Z T, FENG H Z, et al. Sphingomyelin synthase 2 promotes an aggressive breast cancer phenotype by disrupting the homoeostasis of ceramide and sphingomyelin[J].Cell Death Dis, 2019, 10(3):157.
[24] CORCELLE-TERMEAU E, VINDELØV S D, HÄMÄLISTÖS,et al. Excess sphingomyelin disturbs ATG9A trafficking and autophagosome closure[J]. Autophagy, 2016, 12(5):833-849.
[25] HORVATH S E, DAUM G. Lipids of mitochondria[J]. Prog Lipid Res, 2013, 52(4):590-614.
[26] MORO K, NAGAHASHI M, GABRIEL E, et al. Clinical application of ceramide in cancer treatment[J]. Breast Cancer,2019, 26(4):407-415.
[27] ZHOU X T, HUANG F R, MA G, et al. Dysregulated ceramides metabolism by fatty acid 2-hydroxylase exposes a metabolic vulnerability to target cancer metastasis[J]. Signal Transduct Target Ther, 2022, 7(1):370.

Characteristics of serum lipidomics among Kazakhs with esophageal squamous cell carcinomas based on the UPLC-MS/MS method

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	HUANG Conggai, LIU Qing, ZHENG Shutao, LIU Tao, TAN Yiyi, PENG Tianyuan, CHEN Jiao, LU Xiaomei. Expression of CXCR2 in esophageal cancer tissues and its impact on biological behavior of esophageal cancer cells [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2024, 36(1): 53-57,65.
[2]	ZHENG Yaqi, ZHAO Ziting, PAN Deyuan, LIU Luxin, XU Xiue, LIAO Liandi, WANG Shaohong, LI Enmin, XU Liyan. The expression of tonsoku-like DNA repair protein in esophageal carcinoma and its effect on the proliferation of esophageal squamous cell carcinoma [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2023, 35(6): 412-419.
[3]	WANG Yinong, LIU Guozheng, XIE Guanchao, FENG Dan, LI Sai, CAI Yan, ZHANG Yu, WANG Mingrong, HAO Jiajie. Inhibitory effects of ANXA2 knockdown on malignant phenotype of esophageal squamous carcinoma cells [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2023, 35(6): 445-451.
[4]	LIU Ruixue, ZHANG Liwei. Expression and significance of AMPK esophageal squamous cell carcinoma among Kazakhs [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2023, 35(4): 285-291.
[5]	SHI Jianhong, CHEN Dingxiong, LU Xiaotong, HAO Jiajie, CAI Yan, WANG Mingrong, ZHANG Yu. Inhibitory effect of ICG-001 on proliferation of esophageal squamous carcinoma cells and its molecular mechanisms [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2023, 35(3): 187-191,196.
[6]	FENG Dan, FAN Zhilu, WANG Yinong, LI Sai, GUO Jing, CAI Yan, ZHANG Yu, WEI Wenqiang, WANG Mingrong, HAO Jiajie. P4HA2 promotes proliferation of esophageal squamous carcinoma cells via activating the EGFR/AKT/S6 signaling pathway [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2023, 35(2): 87-94,101.
[7]	LI Ziyao, ZHANG Haiping, MADINIYET·Niyaz, JULATI·Ainiwaer, ZHANG Liwei, EDRIS·Awut. Clinicopathological significance of cystatin 6 protein expression in Kazakh esophageal squamous cell carcinoma [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2022, 34(6): 429-433,438.
[8]	CUI Wenxuan, JIAO Wenjing, ZHAO Wei, DU Yanyan, TIAN Guo, ZHANG Jinyan, MA Ming. Clinical values of combined FIB, FAR and serum tumor markers in diagnosis and progression of ESCC patients [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2022, 34(4): 289-294,326.
[9]	YANG Xingxiao, ZHANG Xueyuan, ZOU Naiyi, SHAN Bao'en, MA Ming, ZHU Shuchai. Effects of HMGB1 silencing on migration, invasion and radiosensitivity of esophageal squamous cell carcinoma cells [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2021, 33(5): 327-333.
[10]	YANG Liyan, LIU Zou, HAO Jiajie, ZHANG Yu, WANG Mingrong. Study on the mechanism of nucleo-plasma translocation of p62 protein in esophageal squamous cell carcinoma [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2021, 33(5): 338-344.
[11]	CHANG Chen, YANG Liyan, CAI Hongqing, YUAN Qing, HAO Jiajie, WANG Mingrong. Expressions and clinical implications of SERPINE1 mRNA in esophageal squamous carcinoma tissues [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2021, 33(4): 245-249.
[12]	ZHENG Junwen, CHANG Chen, HAO Jiajie, CAI Yan, WANG Mingrong, ZHANG Yu. Investigation on expression and function of NEDD4 in esophageal squamous cell carcinoma [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2021, 33(3): 203-207,224.
[13]	JIAO Wenjing, GUO Xiujuan, SHAO Junguo, JIAO Wenpeng, ZHANG Jinyan. Relationships among blood cell ratios, clinicopathological characteristics and prognosis in esophageal squamous cell carcinoma [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2021, 33(3): 213-217.
[14]	ZHANG Die, LIU Xianghe, HUO Miaomiao, LIU Mei, XU Ningzhi, ZHU Hongxia. Effects of miR-195-5p on radiosensitivity of esophageal squamous cell carcinoma cells [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2021, 33(2): 81-88,94.
[15]	ZHANG Na, FAN Zhilu, YANG Liyan, CHANG Chen, CAI Yan, HAO Jiajie, WANG Mingrong. Clinical significance of decreased SERPINB5 expression in esophageal squamous cell carcinomas [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2021, 33(2): 101-109.